Mizuho increased the price target for DexCom (DXCM) from $78 to $90 following impressive earnings. Elemements within DexCOM leadership made strategic stock sales. The company shares swung in value leading to numerous debates regarding DexCom's accurate valuation. Investment firms started increasing their shares in DXCM and there is the expansion of the Continuous Glucose Monitoring (CGM) market driven by DexCom leadership. DexCom's financials showed strong balance even as some executives sold stock. The company's glucose monitoring technology showcases potential for development. DXCM stock wobbled even after getting FDA clearance for Dexcom Smart Basal. New shares of DexCom were purchased by Iron Triangle Partners LP as new investment. With the release of DexCom's Q4 unrevealed results, it's noted that DexCom's CGM features will continue to grow as new RSUs are granted to the CFO. Questions on the price reflects long-term returns and their stock performance emerged. DexCom (DXCM) underwent a management shift with Jake Leach becoming its new President and CEO lead. Investors are encouraging stock purchases citing Dexcomβs rapid expansion and robust financial performance.
Dexcom DXCM News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 21 Mar 2026 01:55:30 GMT -
Rating 5
- Innovation 8
- Rumor 1
